Disease Outbreaks

When global health is at risk – from Ebola, COVID-19, mpox, or otherwise – experience matters.

MRIGlobal has a long history of operation, maintenance, and sustainment of biological safety laboratories, including our operational pathogen detection and diagnostic surveillance programs, and associated research, development, testing and evaluation programs.

Our facilities include:

  • 12,000 sq. ft. of BSL-2 laboratory space with 1,500 sq. ft. of CAP-accredited clinical laboratories, and 1,800 sq. ft. of BSL-3 laboratory space
  • NGS laboratories that now include 7 Illumina MiSeqs (including one MiSeqDx) and one iSeq
  • Operational pathogen detection and diagnostic surveillance programs, and associated research, development, testing and evaluation (RDT&E) programs
  • Quality management system (QMS) that is certified (ISO-9001:2008) and has a successful audit history with the FDA, CAP, ISO, CDC, and USDA

MRIGlobal has decades of experience partnering with government agencies and commercial clients, including:

  • U.S. Department of Defense (DOD)
  • U.S. Department of Health and Human Services (HHS)
  • Department of Homeland Security (DHS)
  • HHS’s Biomedical Advanced Research and Development Authority (BARDA) to develop, validate, and submit for 510(k) clearance, a rapid blood test for anthrax infection that will be transferred to and used by public health laboratories
  • Consortium for Microbial Forensics and Genomics, funded by DHS to prepare high-quality genome sequences of bacterial, viral, and fungal select agents
  • DOD Microbial Forensic Initiative Laboratory (MFIL) and Defense Threat Reduction Agency’s Sample-to-Sequence (S2S) programs

MRIGlobal Capabilities for Testing Clinical and Dangerous Pathogens:

Virology, Bacteriology Stock Production and Testing
  • Viral stocks and propagation
  • High path influenza, RSV, etc.
  • Tissue culture
  • TCID50, Plaque Assays, HAI, Flow Cytometry, ELISA
In vitro Diagnostics and Clinical Support Assays
  • GLP, ISO9001, CAP/CLIA Laboratory, QMS and Regulatory Support
  • Exclusivity/inclusivity, verification and validation Studies, pre-subs at BSL-2&3 laboratory levels
Molecular and Immuno- and Cell-based Assay Development
  • Multiple qPCR/RTPCR and molecular platforms
  •  Lateral flow assays and technology support
NGS and Bioinformatics
  • Multiple Illumina platforms, bioinformatics, databases
In vivo Testing Experience
  • Rodent, ferret, mini-pig, non-human primate models
  • DVM on staff, IACUC, biosafety team
  • Multiple routes of exposure
Mobile Laboratory and Containerized Bio-containment Systems
  • Designing, building, deploying, and staffing mobile diagnostic and testing laboratories
  • Clinical patient containment air-transport modules
Biosafety and Biosecurity Preparedness
  • Emergency and pandemic response plans and assessments
  • Facility risk assessments
  • Threat assessment decision matrices
  • Biosafety training
  • On-call consultation
  • Annual reviews of infectious disease programs

Our Staff

Gene Olinger, Ph.D.

For 20+ years, Gene has provided multidisciplinary expertise across immunology, infectious disease, host-pathogen interactions, vaccine technology platforms, and virology. He has extensive experience in development of medical countermeasures ranging from prophylactic treatments, vaccines, diagnostics, and therapeutics. Gene’s team in collaboration with international partners developed the first successful antibody treatment for Ebola virus disease, ZMapp.

> Read more about Gene’s work with COVID-19 in his Scientist Spotlight




Dr. Gene Olinger
Work With Us

MRIGlobal is committed to finding solutions for a safer, healthier world.